BioInvent’s partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer

LUND, Sweden, April 12, 2021 / PRNewswire / – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data from a phase I dose escalation study of TB-403 in pediatric subjects with recurrent or refractory medulloblastoma (MB) at the American Association for Cancer Research (AACR) annual meeting.

The Phase I study concluded that the results warrant further evaluation of TB-403 in pediatric patients with relapsed or refractory medulloblastoma (MB). TB-403 has an orphan designation for medulloblastoma from the European Medicines Agency (EMA). For more information and the full press release, please visit https://www.oncurious.com/news-events/latest-news.

TB-403 is an anti-PIGF (anti-placental growth factor) antibody and is currently being developed by Oncurious NV, a subsidiary of Oxurion NV. TB-403 was previously jointly developed by BioInvent and Oncurious but, as previously informed, is no longer one of BioInvent’s focus projects. BioInvent has no further development costs for the project, but has retained rights to 50 percent of future revenues after deducting some of the past development costs and all future development costs related to TB-403.

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company discovering and developing new and world-class immunomodulating antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase I / II trials for the treatment of haematological cancer and solid tumors, respectively. The company’s validated, patented FIRST ™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnerships.

The Company generates revenues from research collaborations and licensing agreements with several leading pharmaceutical companies, as well as from the production of antibodies for third parties in the Company’s fully integrated manufacturing facility. More information is available at www.bioinvent.com.

For more information, please contact:

Cecilia Hofvander
Senior Director Investor Relations
+46 (0) 46 286 85 50
[email protected]

BioInvent International AB (publ)

Co. Reg. No. Org no: 556537-7263
Visiting address: Ideongatan 1
Postal address: 223 70 LUND
Telephone: +46 (0) 46 286 85 50
www.bioinvent.com

The information was submitted for publication on April 12, 2021 at 7:30 a.m. CEST.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioinvent-international-ab/r/bioinvent-s-partner-oncurious-nv-presents-phase-i-data-on-tb-403-in-pediatric-cancer,c3323127

The following files are available for download:

SOURCE BioInvent International AB

Comments are closed.